Skyeline Management Ltd is Director & 10% Owner at Royalty Pharma plc (RPRX). They have made 2 open-market trades across 1 company since 2022, most recently 2022-12-02.
CIK 0001814877
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RPRX | 7,879,374 | $480.4M |
Shares reported on the most recent Form 4, priced at the 2022-12-05 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.